| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
|
Lancet
|
2010
|
9.72
|
|
2
|
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
|
Lancet
|
2010
|
8.41
|
|
3
|
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
|
J Clin Oncol
|
2009
|
5.37
|
|
4
|
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
|
N Engl J Med
|
2012
|
5.31
|
|
5
|
Rethinking ovarian cancer: recommendations for improving outcomes.
|
Nat Rev Cancer
|
2011
|
5.28
|
|
6
|
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
|
J Clin Oncol
|
2012
|
3.86
|
|
7
|
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
|
J Clin Oncol
|
2011
|
3.71
|
|
8
|
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.
|
PLoS Genet
|
2013
|
2.39
|
|
9
|
The Y deletion gr/gr and susceptibility to testicular germ cell tumor.
|
Am J Hum Genet
|
2005
|
2.26
|
|
10
|
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.
|
Int J Gynecol Cancer
|
2011
|
2.24
|
|
11
|
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci.
|
Hum Mol Genet
|
2006
|
2.23
|
|
12
|
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).
|
Int J Gynecol Cancer
|
2011
|
2.09
|
|
13
|
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
|
Clin Cancer Res
|
2011
|
1.79
|
|
14
|
Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study.
|
J Clin Oncol
|
2012
|
1.73
|
|
15
|
Assessing health-related quality of life in gynecologic oncology: a systematic review of questionnaires and their ability to detect clinically important differences and change.
|
Int J Gynecol Cancer
|
2010
|
1.72
|
|
16
|
The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred.
|
Urol Oncol
|
2009
|
1.70
|
|
17
|
Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.
|
J Clin Oncol
|
2014
|
1.69
|
|
18
|
The fertility-related concerns, needs and preferences of younger women with breast cancer: a systematic review.
|
Breast Cancer Res Treat
|
2009
|
1.52
|
|
19
|
Improving cancer outcomes through international collaboration in academic cancer treatment trials.
|
J Clin Oncol
|
2009
|
1.43
|
|
20
|
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.
|
Cancer Res
|
2012
|
1.39
|
|
21
|
Oxaliplatin-induced neurotoxicity and the development of neuropathy.
|
Muscle Nerve
|
2005
|
1.37
|
|
22
|
Biology of epithelial ovarian cancer: implications for screening women at high genetic risk.
|
J Clin Oncol
|
2004
|
1.33
|
|
23
|
Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA).
|
Breast Cancer Res
|
2003
|
1.25
|
|
24
|
It's now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer--an Australian fertility decision aid collaborative group study.
|
J Clin Oncol
|
2011
|
1.20
|
|
25
|
The role of BRCA mutation testing in determining breast cancer therapy.
|
Nat Rev Clin Oncol
|
2010
|
1.18
|
|
26
|
Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study.
|
BMC Cancer
|
2006
|
1.16
|
|
27
|
The fertility- and menopause-related information needs of younger women with a diagnosis of breast cancer: a qualitative study.
|
Psychooncology
|
2003
|
1.14
|
|
28
|
Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors.
|
Genes Chromosomes Cancer
|
2008
|
1.05
|
|
29
|
Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda.
|
Breast Cancer Res
|
2008
|
1.05
|
|
30
|
Cancer of the ovary, fallopian tube, and peritoneum.
|
Int J Gynaecol Obstet
|
2012
|
1.03
|
|
31
|
Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma.
|
Int J Gynecol Cancer
|
2014
|
1.01
|
|
32
|
Oxaliplatin and axonal Na+ channel function in vivo.
|
Clin Cancer Res
|
2006
|
1.00
|
|
33
|
Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer.
|
Int J Gynecol Cancer
|
2010
|
0.96
|
|
34
|
Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study.
|
Int J Gynecol Cancer
|
2010
|
0.96
|
|
35
|
Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer.
|
J Natl Cancer Inst
|
2011
|
0.96
|
|
36
|
A fibroid or cancer? A rare case of mixed choriocarcinoma and epithelioid trophoblastic tumour.
|
Case Rep Obstet Gynecol
|
2013
|
0.96
|
|
37
|
The impact of aromatase inhibitors on sexual functioning: current knowledge and future research directions.
|
Breast
|
2008
|
0.90
|
|
38
|
Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count.
|
Clin Colorectal Cancer
|
2006
|
0.89
|
|
39
|
The experience of cancer-related fatigue and chronic fatigue syndrome: a qualitative and comparative study.
|
J Pain Symptom Manage
|
2007
|
0.88
|
|
40
|
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix.
|
Int J Gynecol Cancer
|
2014
|
0.88
|
|
41
|
Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
|
Gynecol Oncol
|
2007
|
0.87
|
|
42
|
Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.
|
J Clin Oncol
|
2013
|
0.87
|
|
43
|
Hormonal treatment in recurrent and metastatic gynaecological cancers: a review of the current literature.
|
Curr Oncol Rep
|
2013
|
0.85
|
|
44
|
The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
|
Asia Pac J Clin Oncol
|
2011
|
0.85
|
|
45
|
If I am in the mood, I enjoy it: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer.
|
Oncologist
|
2011
|
0.85
|
|
46
|
Development and pilot testing of a fertility decision aid for young women diagnosed with early breast cancer.
|
Breast J
|
2010
|
0.85
|
|
47
|
Paraneoplastic mononeuritis multiplex in non-small-cell lung carcinoma.
|
J Clin Neurosci
|
2006
|
0.84
|
|
48
|
Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.
|
J Clin Oncol
|
2011
|
0.84
|
|
49
|
Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity.
|
Clin Colorectal Cancer
|
2006
|
0.84
|
|
50
|
Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009.
|
Int J Gynecol Cancer
|
2010
|
0.83
|
|
51
|
A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer.
|
Gynecol Oncol
|
2004
|
0.83
|
|
52
|
How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer.
|
BMC Cancer
|
2012
|
0.83
|
|
53
|
The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer.
|
J Sex Med
|
2013
|
0.82
|
|
54
|
Prevalence and predictors of insomnia in women with invasive ovarian cancer: anxiety a major factor.
|
Eur J Cancer
|
2009
|
0.82
|
|
55
|
Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation.
|
Gynecol Oncol
|
2003
|
0.81
|
|
56
|
Quality of life and patient-reported outcomes in endometrial cancer clinical trials: a call for action!
|
Int J Gynecol Cancer
|
2014
|
0.81
|
|
57
|
Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma.
|
Int J Gynecol Cancer
|
2014
|
0.80
|
|
58
|
Younger age-at-diagnosis for familial malignant testicular germ cell tumor.
|
Fam Cancer
|
2009
|
0.80
|
|
59
|
Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature.
|
Australas J Dermatol
|
2013
|
0.80
|
|
60
|
Role of systemic chemotherapy in metastatic cervical cancer.
|
Expert Rev Anticancer Ther
|
2003
|
0.79
|
|
61
|
Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study.
|
J Gynecol Oncol
|
2013
|
0.78
|
|
62
|
Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing.
|
Oncol Nurs Forum
|
2013
|
0.78
|
|
63
|
Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas.
|
Gynecol Oncol
|
2005
|
0.77
|
|
64
|
Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas.
|
Pathology
|
2006
|
0.77
|
|
65
|
A specialist breast care nurse role for women with metastatic breast cancer: enhancing supportive care.
|
Oncol Nurs Forum
|
2011
|
0.77
|
|
66
|
Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors.
|
Int J Gynecol Cancer
|
2014
|
0.77
|
|
67
|
Treatment of recurrent ovarian cancer.
|
Chang Gung Med J
|
2004
|
0.76
|
|
68
|
An Exercise Intervention During Chemotherapy for Women With Recurrent Ovarian Cancer: A Feasibility Study.
|
Int J Gynecol Cancer
|
2015
|
0.76
|
|
69
|
Quantifying physical activity and the associated barriers for women with ovarian cancer.
|
Int J Gynecol Cancer
|
2015
|
0.76
|
|
70
|
Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary.
|
Int J Gynecol Cancer
|
2014
|
0.76
|
|
71
|
Carboplatin dosing in ovarian cancer: problems and pitfalls.
|
Int J Gynecol Cancer
|
2011
|
0.76
|
|
72
|
Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.
|
Nature
|
2015
|
0.75
|
|
73
|
Feeding preferences of mesograzers on aquacultured Gracilaria and sympatric algae.
|
Aquaculture
|
2011
|
0.75
|
|
74
|
Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy.
|
Clin Colorectal Cancer
|
2007
|
0.75
|
|
75
|
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers.
|
Int J Gynecol Cancer
|
2014
|
0.75
|
|
76
|
Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required.
|
Am J Surg Pathol
|
2017
|
0.75
|
|
77
|
Stage IB2 adenosquamous cervical cancer diagnosed at 19-weeks' gestation.
|
Aust N Z J Obstet Gynaecol
|
2014
|
0.75
|
|
78
|
No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.
|
Gynecol Oncol
|
2004
|
0.75
|
|
79
|
CART-WHEEL.org can facilitate research into rare gynecological tumors.
|
Int J Gynecol Cancer
|
2011
|
0.75
|